TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OPTIRAY 240

IOVERSOL
Approved 1988-12-30
Jump to: Indications Approvals Trials Competitors Safety Patents
8
Indications
--
Phase 3 Trials
37
Years on Market

Details

Status
Discontinued
First Approved
1988-12-30
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

LIEBEL-FLARSHEIM
Active Ingredient: IOVERSOL

OPTIRAY 240 Approval History

Loading approval history...

What OPTIRAY 240 Treats

8 FDA approvals

Originally approved for its first indication in 1988 . Covers 8 distinct patient populations.

  • Other (8)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OPTIRAY 240 FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA019710 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.